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Abstract
Background: Choroidal neovascular membrane (CNVM) is one of the leading causes of severe visual loss and
is often associated with age-related macular degeneration (AMD). Various modalities of treatment, including
photocoagulation and surgery, are being considered as options, but with limited success. Prostate-specific
membrane antigen (PSMA) is a type II membrane glycoprotein expressed in benign and malignant prostatic tissues,
in some non-prostatic tissues, and in the endothelium of tumor-associated neovasculature of non-prostatic
neoplasm. Some studies have suggested that the expression of PSMA is restricted to endothelium from tumor-
associated neovasculature and might be stimulated by some tumor-secreted angiogenic factors. However, no
previous study demonstrating PSMA expression in non-related tumor neovasculature, such as CNVM, has been
performed to date. Furthermore, demonstration of PSMA expression in CNVM in AMD patients could reveal a
novel target for antineovascular therapy. The purpose of this study was to evaluate the immunohistochemical
expression of PSMA in CNVM from AMD.
Methods: Immunohistochemical analysis, with a standard avidin-biotin complex technique, was performed using
an anti-PSMA mouse monoclonal antibody in 30 specimens of surgically excised CNVM from AMD patients.
Antibody to an endothelial cell specific marker, factor VIII, was used to confirm the location of the endothelial
cells.
Results: The angiogenic microvessels of the 30 cases demonstrated negative staining to PSMA while factor VIII
was expressed in all cases. Seventy-five percent of the secretory-acinar epithelium of the prostatic hyperplasia
specimen stained positive, confirming that the immunohistochemical technique was correctly performed.
Conclusion: The absence of PSMA expression in non-tumoral neovasculature supports the theory, previously
suggested, that endothelial cell PSMA expression may be stimulated by one or more tumor-secreted angiogenic
factors. Angiogenesis is very important in neoplasia and the endothelial expression of PSMA in tumor-associated
neovasculature may represent a target for antineovasculature-based therapy. The absence of PSMA expression in
CNVM suggests that PSMA may not be a potential target for antineovasculature-based therapy.
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Background
Age-related macular degeneration (AMD) is the principal
cause of registered legal blindness among those over 65
years of age in the United States, Western Europe, Aus-
tralia, Canada and Japan [1-5]. The clinical hallmarks of
AMD are the formation of drusen, geographic atrophy
and, in advanced stage, choroidal neovascular membrane
(CNVM). The mechanism of CNVM formation is growth
of new vessels from the choriocapillaris through Bruch's
membrane and subsequent extension into the subretinal
pigment epithelium, subretinal space, or a combination
of both [6-8]. Various modalities of treatment, including
photocoagulation and surgery, are being considered as
options, but with limited success.
Prostate-specific membrane antigen (PSMA) is a 100 kDa
type II transmembrane glycoprotein, located on chromo-
some 11p, initially characterized by the monoclonal anti-
body (mAb) 7E11 [9,10]. Although PSMA exhibits in vitro
neuropeptidase and folate hydrolase activity, its function
in vivo has not been fully elucidated [11,12]. PSMA is
strongly expressed in benign prostatic secretory-acinar
epithelium, prostatic intraepithelial neoplasia, and pros-
tatic adenocarcinoma [10,13]. PSMA expression is also
described in other benign tissues, including a subset of
proximal renal tubules and duodenum mucosa [13,14],
and in non-prostatic malignant tumor neovasculature
[15]. Studies have suggested that PSMA expression is
restricted to tumor-related neovasculature and might be
stimulated by tumor-secreted angiogenic factors. How-
ever, this hypothesis cannot be validated since no charac-
terization of PSMA expression in non-related tumor
neovascularization, such as CNVM, has been performed
to date.
The purpose of this study was to characterize the immu-
nohistochemical expression of PSMA in CNVM associated
with AMD. The presence or absence of this protein in
CNVM could contradict or support the theory that
endothelial cell PSMA expression is tumor related. Fur-
thermore, the presence of PSMA could be a new potential
target for antineovascular therapy in cases of AMD.
Materials and methods
Thirty surgically excised CNVM samples obtained at vit-
rectomy from patients with AMD were collected from the
archives of the Henry C. Witelson Ocular Pathology Lab-
oratory and Registry, McGill University, Montreal, Can-
ada. Each specimen was formalin-fixed and paraffin-
embedded and contained sufficient material for H&E
staining and immunoassaying. Immunohistochemistry
was performed according to the avidin-biotin complex
(ABC) technique. Briefly, 60 sections were deparaffinized
in xylene and rehydrated through graded ethanol washes.
Ten minutes incubation in boiling citrate buffer (pH 6.0)
was used for antigen retrieval. To block endogenous per-
oxidase, incubation with 3% hydrogen peroxidase in
methanol for 5 minutes was performed. Non-specific
binding was blocked with a 30 minute wash with 1%
bovine serum albumin (BSA) in Tris-buffered saline (TBS,
pH 7.6). The anti-PSMA mouse mAb (Novocastra, New-
castle, UK) was applied in dilution 1:50 in 30 specimens,
and incubated overnight at 4°C. Anti-factor VIII mouse
mAb [16] (DAKO, Ontario, Canada), in dilution 1:100,
was also used in 30 sequencial slides of the same speci-
mens to demonstrate the correct location of the endothe-
lial cells. Following this, the slides were incubated with
rabbit anti-mouse secondary mAb E0354 (diluted 1:500;
DAKO, Ontario, Canada) for 30 minutes at 37°C. Sec-
tions were then incubated with horseradish peroxidase-
conjugated ABC complex (DAKO, Ontario, Canada) for
30 minutes at 37°C. Immunostaining was visualized
using 3-amino-9-ethylcarbazole (AEC) chromogen
(DAKO, Ontario, Canada). Finally, the slides were coun-
terstained with Giu-II haematoxylin and cover-slipped.
Prostatic hyperplasia and tonsil were used as positive con-
trols. Negative control sections were incubated with non-
immune serum (0.1% BSA in TRIS) instead of the primary
antibody.
Samples were classified in two categories: negative (if
none of the endothelial cells displayed immunostaining)
and positive (if any endothelial cell displayed distinctive
immunostaining, irrespective of the staining intensity). In
addition, for each specimen the percentage of cells stained
(less than 5% = 0; 6% to 25% = 1; 26% to 50% = 2; 51%
to 75% = 3; and greater than 75% = 4) was determined.
This criterion has been previously used [17].
Results
To evaluate the PSMA expression, immunohistochemical
analyses with anti-PSMA and anti-factor VIII mAbs were
performed in 30 cases of CNVM. The endothelial cells of
the angiogenic microvessels of all the cases demonstrated
negative staining to PSMA (Figure 1a,1b) while factor VIII
was expressed in the endothelial cells of all CNVM
sequencial slides (Figure 2). Seventy-five percent of the
prostatic secretory-acinar epithelium of the prostatic
hyperplasia specimen (Figure 3) used as positive control,
stained positive. This confirmed that the immunohisto-
chemical technique was correctly performed.
Discussion
The PSMA protein's name may be misleading since its
expression is not confined exclusively to the prostate. It
has also been reported in select benign non-prostatic tis-
sues such as duodenal columnar epithelium, proximal
renal tubular epithelium, colonic ganglion cells and
benign breast epithelium [9,13-15,18].Journal of Carcinogenesis 2006, 5:21 http://www.carcinogenesis.com/content/5/1/21
Page 3 of 4
(page number not for citation purposes)
Several immunohistochemical studies have examined
expression of PSMA in non-prostatic primary tumor neo-
vasculature. Silver et al [14] demonstrated the expression
of PSMA in endothelial cells in a subset of tumors includ-
ing renal cell carcinoma, transitional cell carcinoma of the
urinary bladder, and colonic adenocarcinoma. More
recently, Chang et al [19] examined multiple anti-PSMA
antibodies and showed that each antibody consistently
bound the tumor-associated neovasculature in cases of
testicular embryonal carcinoma, neuroendocrine carci-
noma, malignant skin melanoma, pancreatic duct carci-
noma, non-small cell lung carcinoma, soft tissue sarcoma,
and breast carcinoma. In our laboratory, a previous study
(unpublished data) demonstrated that PSMA is not
expressed in neovasculature associated to uveal
melanoma or in malignant uveal melanocytes (Figure 4).
Interestingly, neither the vascular endothelial cells of
benign tissues nor the neoplastic cells of vascular tumors
expressed PSMA [19]. These results suggest that endothe-
lial cell PSMA expression may be restricted to tumor-asso-
ciated neovasculature and is probably stimulated by some
Secretory-acinar epithelium of a hyperplastic prostate stained  positive to PSMA, 400× Figure 3
Secretory-acinar epithelium of a hyperplastic prostate stained 
positive to PSMA, 400×.
Endothelial cells of choroidal neovascular membrane stained  positive to factor-VIII, 400× Figure 2
Endothelial cells of choroidal neovascular membrane stained 
positive to factor-VIII, 400×.
Endothelial cells of choroidal neovascular membrane stained negative to PSMA, 200× (a) and 400× (b, arrow) Figure 1
Endothelial cells of choroidal neovascular membrane stained negative to PSMA, 200× (a) and 400× (b, arrow).Journal of Carcinogenesis 2006, 5:21 http://www.carcinogenesis.com/content/5/1/21
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tumor-secreted angiogenic factors [19]. RT-PCR and in situ
hybridization analyses have also demonstrated that PSMA
protein is produced by endothelial cells of tumor-associ-
ated neovasculature instead of being sequestered from the
serum or from the surrounding stromal cells [18]. How-
ever, the hypothesis that PSMA is specifically expressed by
endothelial cells from tumor-related neovasculature
should not be unconditionally accepted since PSMA
expression in benign neovasculature has not yet been
established.
The purpose of this study was to characterize the PSMA
expression in 30 cases of benign neovasculature, while
confirming the idea that endothelial cell PSMA expression
is restricted to tumor-associated neovasculature. Factor
VIII, a specific endothelial marker, was used to demon-
strate the exact location of the endothelial cells [16]. Fur-
thermore, if PSMA is present in CNVM, it may represent a
potential target for antineovasculature-based therapy in
cases of AMD.
Conclusion
Since none of the 30 cases of CNVM expressed PSMA, this
protein may not represent a new target for antineovascu-
lature-based therapy in cases of AMD. Further studies will
need to be done to validate this hypothesis. Based on the
results of the present study, the hypothesis that endothe-
lial cell PSMA expression is restricted to tumor-associated
neovasculature is plausible. However, the PSMA expres-
sion in other benign neovasculature tissue, such as granu-
lation tissue, remains to be established.
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Endothelial cell of neovascularization related to uveal  melanoma and malignant melanocytes stained negative to  PSMA Figure 4
Endothelial cell of neovascularization related to uveal 
melanoma and malignant melanocytes stained negative to 
PSMA.